According to our own findings and a literature survey, we found that T-ALL patients with <i>SET-CAN/NUP214</i> fusion usually shows early resistance to chemotherapy, but they have a delayed response, and the CR rate is not compromised; thus, a chemotherapy regimen featuring a 28-day long course, such as that used in GRAALL 2003 or 2005, is recommended for induction therapy. This evidence concerns the gene NUP214 and acute lymphoblastic leukemia.